Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2024

Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world data

Current Medical Research and Opinion 2024;40:1993–2002 doi: 10.1080/03007995.2024.2416979.

Gammeltoft Gerwien J,

Treuer T,

Zaremba-Pechmann L,

Smolen JS

Edwards et al. report on real-world data for baricitinib monotherapy in rheumatoid arthritis, showing significant disease activity reduction across multiple registries and observational studies. These findings reinforce the viability of baricitinib monotherapy in clinical practice for RA patients, complementing existing guidelines.

Keywords:

June 2024

Phase 2 trial of deucravacitinib in psoriatic arthritis: Biomarkers associated with disease activity, pharmacodynamics, and clinical responses

Arthritis Rheumatol 2024 doi: 10.1002/art.42921 Epub ahead of print

Gao L,

Hu Y,

Nowak M,

Banerjee S,

Catlett I

FitzGerald, et al. found that Deucravacitinib significantly impacted biomarkers associated with TYK2 signalling pathways of key inflammatory cytokines, including IL-23 and Type I IFN, and those related to collagen matrix turnover.

Keywords:

April 2024

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

Ann Rheum Dis 2024 doi: 10.1136/ard-2024-225531 Epub ahead of print

Eder L,

Mauro D,

Nash P,

van der Helm-van Mil A,

Zabotti A,

van der Heijde D,

Smolen JS

The 2023 EULAR recommendations provided an updated consensus on the pharmacological management of PsA with a new overarching principle and recommendation for 2023. Recent MOA safety data emphasised the importance of patient-specific benefit-risk profiling in JAKi therapy, and extra-musculoskeletal (MSK) manifestations related to PsA should be considered during drug selection.